These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38640606)

  • 1. Impact of pCR after neoadjuvant chemotherapy and radical D2 dissection in locally advanced gastric cancers: Analysis of 1001 cases.
    Bhandare MS; Gundavda KK; Yelamanchi R; Chopde A; Batra S; Kolhe M; Ramaswamy A; Ostwal V; Deodhar K; Chaudhari V; Shrikhande SV
    Eur J Surg Oncol; 2024 Jun; 50(6):108343. PubMed ID: 38640606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 3. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.
    Sun X; Lyu J; Yang M; Lin Y; Wu K; Liu K; Li A; Shuai X; Cai K; Wang Z; Wang G; Zhang P; Yin Y; Tao K
    Ann Surg Oncol; 2024 Nov; 31(12):8157-8169. PubMed ID: 39154154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 6. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
    Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
    Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy
    Li Y; Ma FH; Xue LY; Tian YT
    World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy.
    Song Y; Hirata Y; Ajani JA; Blum Murphy M; Li JJ; Das P; Minsky BD; Mansfield PF; Ikoma N; Badgwell BD
    Ann Surg Oncol; 2024 Oct; 31(10):6918-6930. PubMed ID: 39048909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
    Misirlioglu HC; Coskun-Breuneval M; Kucukpilakci B; Ugur VI; Elgin Y; Demirkasimoglu T; Kara SP; Ozgen A; Sanri E; Guney Y
    Asian Pac J Cancer Prev; 2014; 15(20):8871-6. PubMed ID: 25374221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
    Martin-Romano P; Sola JJ; Diaz-Gonzalez JA; Chopitea A; Iragorri Y; Martínez-Regueira F; Ponz-Sarvise M; Arbea L; Subtil JC; Cano D; Ceniceros L; Legaspi J; Hernandez JL; Rodríguez J
    Br J Cancer; 2016 Sep; 115(6):655-63. PubMed ID: 27537382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 14. Total Neoadjuvant Therapy (TNT) with Full Dose Concurrent Chemotherapy in Locally Advanced Rectal Adenocarcinoma Including Signet Ring and Mucinous Cancers.
    John AO; Singh A; Bala D; Joel A; Georgy JT; Jesudasan MR; Mittal R; Ram TS; Reddy JR; Murthy A; Chandramohan A; Eapen A; Masih D; Ramnath N; Dobrosotskaya I; Yadav B; Chacko RT
    J Gastrointest Cancer; 2024 Mar; 55(1):307-317. PubMed ID: 37479897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?
    Turgeon MK; Gamboa AC; Rupji M; Lee RM; Switchenko JM; El-Rayes BF; Russell MC; Cardona K; Kooby DA; Staley CA; Maithel SK; Shah MM
    Ann Surg Oncol; 2021 Jan; 28(1):97-105. PubMed ID: 32524459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients].
    Wu H; Wang L; He YL; Xu JB; Cai SR; Ma JP; Chen CQ; Zhang XH; Zhan WH
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):509-13. PubMed ID: 24257302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic response in patients with curative resection with D2 dissection following neoadjuvant treatment for locally advanced gastric and esophagogastric junction adenocarcinoma.
    Alemdar A; Duman MG; Sengiz Erhan S; Sasako M
    Eur J Surg Oncol; 2024 Jul; 50(7):108428. PubMed ID: 38795679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
    Yan D; Dai H
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of gastric adenocarcinoma with postoperative chemoirradiation. A non-randomized comparison of oral UFT and 5-FU.
    Surenkok S; Beyzadeoglu M; Oysul K; Ozyigit G; Ataergin S; Arpaci F; Ozet A
    Tumori; 2008; 94(1):70-4. PubMed ID: 18468338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
    Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
    BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.